BridgeMD
New treatment option for Advanced Solid Tumor
Official title A First-in-human Study of PARP1 Selective Inhibitor, IMP1734, in Participants With Advanced Solid Tumors
ClinicalTrials.gov ID: NCT06253130
What this study is testing
What is IMP1734?
IMP1734 is an investigational medicine, being studied as a potential treatment for advanced solid tumor.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- This study investigates the safety and tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of EIK1003 in participants with advanced solid tumors.
- Phase 2: a mid-size study of how well it works
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 89
You may be able to join if
- Key Breast cancer; must have received at least one prior chemotherapy in neoadjuvant/adjuvant/metastatic setting, must have received hormonal therapy...
- HGSOC or high grade endometrioid EOC, fallopian tube or primary peritoneal cancer; must have received at least one prior platinum-based chemotherapy...
- mCRPC with ongoing ADT, must have received NHA and up to 1 prior line of taxane chemotherapy
- Age ≥ 18 years at the time of informed consent
- Eastern Cooperative Oncology Group (ECOG) performance status ≤1
You likely can't join if
- Any investigational or approved anti-cancer therapies administered within 28 days/ before the first dose of IMP1734
- Have received prior PARP1 selective inhibitors
- Mean resting QTcF \> 470 ms or QTcF \< 340 ms
- Active or untreated central nervous system (CNS) metastases and/or carcinomatous meningitis.
- Infections \- An active hepatitis B/C infection
- Any known predisposition to bleeding
See the full eligibility criteria
- Key Breast cancer; must have received at least one prior chemotherapy in neoadjuvant/adjuvant/metastatic setting, must have received hormonal therapy if HR+,
- HGSOC or high grade endometrioid EOC, fallopian tube or primary peritoneal cancer; must have received at least one prior platinum-based chemotherapy for advanced disease
- mCRPC with ongoing ADT, must have received NHA and up to 1 prior line of taxane chemotherapy
- Age ≥ 18 years at the time of informed consent
- Eastern Cooperative Oncology Group (ECOG) performance status ≤1
- Adequate organ function
- Life expectancy ≥ 12 weeks
- Should have evaluable disease as defined by RECIST1.1 and/or CA125 or PSA
- Female people of childbearing potential and male people must agree to use an effective method of contraception from study entry up to 6 months after the last dose of IMP1734
- deleterious or suspected deleterious germline or somatic mutations of select HRR genes
- up to 1 prior line of PARP inhibitor containing treatment Key
- Any investigational or approved anti-cancer therapies administered within 28 days/ before the first dose of IMP1734
- Have received prior PARP1 selective inhibitors
- Mean resting QTcF \> 470 ms or QTcF \< 340 ms
- Active or untreated central nervous system (CNS) metastases and/or carcinomatous meningitis.
- Infections \- An active hepatitis B/C infection
- Any known predisposition to bleeding
- Unable to swallow oral medications OR have malabsorption syndrome or any other uncontrolled gastrointestinal condition that might impair the bioavailability
The study team makes the final eligibility decision.
Where it's taking place
- Tucson, Arizona, United States
- Little Rock, Arkansas, United States
- Irvine, California, United States
- San Diego, California, United States
- San Francisco, California, United States
- Denver, Colorado, United States
- New Haven, Connecticut, United States
- Celebration, Florida, United States
- Miami, Florida, United States
- Ann Arbor, Michigan, United States
- Detroit, Michigan, United States
- Minneapolis, Minnesota, United States
- St Louis, Missouri, United States
- Hackensack, New Jersey, United States
- Ithaca, New York, United States
- Providence, Rhode Island, United States
- Charleston, South Carolina, United States
- Germantown, Tennessee, United States
- Nashville, Tennessee, United States
- San Antonio, Texas, United States
+ 31 more site(s).
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 89 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Tucson, Arizona, United States; Little Rock, Arkansas, United States; Irvine, California, United States; San Diego, California, United States; San Francisco, California, United States; Denver, Colorado, United States and 45 more location(s). Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.